Butyrate-mediated acquisition of chemoresistance by human colon cancer cells

Kang,Hyang  Ri; Choi,Hyeon  Gyeom; Jeon,Chae  Kyung; Lim,Soo-Jeong; Kim,So  Hee

doi:10.3892/or.2016.4838

Butyrate-mediated acquisition of chemoresistance by human colon cancer cells

Authors:
- Hyang Ri Kang
- Hyeon Gyeom Choi
- Chae Kyung Jeon
- Soo-Jeong Lim
- So Hee Kim
View Affiliations

Affiliations: College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, Republic of Korea, College of Natural Sciences, Hannam University, Daejeon, Republic of Korea, Grinnell College, Grinnell, IA 50112, USA, Department of Bioscience and Biotechnology, Sejong University, Seoul, Republic of Korea
Published online on: May 27, 2016 https://doi.org/10.3892/or.2016.4838
Pages: 1119-1126

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Butyrate is a short-chain fatty acid produced by the intestinal microflora and it not only induces apoptosis but also inhibits the proliferation of cancer cells. Recently, it has been reported that butyrate may cause resistance in colon cancer cells. Therefore, we investigated the effects of increased resistance to butyrate in HCT116 colon cancer cells. We established HCT116 cells resistant to butyrate (HCT116/BR) by treating HCT116 parental cells (HCT116/PT) with increasing concentrations of butyrate to a maximum of 1.6 mM for 3 months. The butyrate concentrations that inhibited cell growth by 50% (IC50) were 0.508 and 5.50 mM in HCT116/PT and HCT116/BR cells. The values after treatment with paclitaxel, 5-fluorouracil (5-FU), doxorubicin and trichostatin A (TSA) were 2.42, 2.36, 4.31 and 11.3-fold higher, respectively, in HCT116/BR cells compared with HCT116/PT cells. The protein expression of drug efflux pumps, such as P-glycoprotein (P-gp), breast cancer-resistant protein (BCRP) and the multidrug resistance associated protein 1 (MRP1), did not differ between HCT116/PT and HCT116/BR cells. The expression level of the anti-apoptotic Bcl-xL protein was increased while those of pro-apoptotic Bax and Bim proteins were reduced in HCT116/BR cells. There were no significant differences in cell motility and invasion. This study suggests that exposure of colon cancer cells to butyrate results in development of resistance to butyrate, which may play a role in the acquisition of chemoresistance in colon cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Gaschott T and Stein J: Short-chain fatty acids and colon cancer cells: The vitamin D receptor - butyrate connection. Recent Results Cancer Res. 164:247–257. 2003. View Article : Google Scholar
3	Vaziri C, Stice L and Faller DV: Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 9:465–474. 1998.PubMed/NCBI
4	Ruemmele FM, Schwartz S, Seidman EG, Dionne S, Levy E and Lentze MJ: Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut. 52:94–100. 2003. View Article : Google Scholar
5	Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R and Van Immerseel F: From the gut to the peripheral tissues: The multiple effects of butyrate. Nutr Res Rev. 23:366–384. 2010. View Article : Google Scholar : PubMed/NCBI
6	Donohoe DR, Collins LB, Wali A, Bigler R, Sun W and Bultman SJ: The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 48:612–626. 2012. View Article : Google Scholar : PubMed/NCBI
7	López de Silanes I, Olmo N, Turnay J, González de Buitrago G, Pérez-Ramos P, Guzmán-Aránguez A, García-Díez M, Lecona E, Gorospe M and Lizarbe MA: Acquisition of resistance to butyrate enhances survival after stress and induces malignancy of human colon carcinoma cells. Cancer Res. 64:4593–4600. 2004. View Article : Google Scholar : PubMed/NCBI
8	Leslie EM, Deeley RG and Cole SP: Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
9	Lepiarczyk M, Kałuża Z, Bielawska A, Czarnomysy R, Gornowicz A and Bielawski K: Cytotoxic activity of octahydropyrazin[2,1-a:5,4-a′]diisoquinoline derivatives in human breast cancer cells. Arch Pharm Res. 38:628–641. 2015. View Article : Google Scholar
10	Han YS, Lee JH and Lee SH: Antitumor effects of fucoidan on human colon cancer cells via activation of Akt signaling. Biomol Ther (Seoul). 23:225–232. 2015. View Article : Google Scholar
11	Lim SJ, Choi HG, Jeon CK and Kim SH: Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells. Oncol Rep. 33:2023–2030. 2015.PubMed/NCBI
12	Song HM, Park GH, Eo HJ, Lee JW, Kim MK, Lee JR, Lee MH, Koo JS and Jeong JB: Anti-proliferative effect of naringenin through p38-dependent downregulation of cyclin D1 in human colorectal cancer cells. Biomol Ther (Seoul). 23:339–344. 2015. View Article : Google Scholar
13	Zhang R, Pan X, Huang Z, Weber GF and Zhang G: Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One. 6:e238312011. View Article : Google Scholar : PubMed/NCBI
14	Cook KL, Shajahan AN, Wärri A, Jin L, Hilakivi-Clarke LA and Clarke R: Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res. 72:3337–3349. 2012. View Article : Google Scholar : PubMed/NCBI
15	Gonçalves P and Martel F: Butyrate and colorectal cancer: The role of butyrate transport. Curr Drug Metab. 14:994–1008. 2013. View Article : Google Scholar : PubMed/NCBI
16	Barrasa JI, Santiago-Gómez A, Olmo N, Lizarbe MA and Turnay J: Resistance to butyrate impairs bile acid-induced apoptosis in human colon adenocarcinoma cells via up-regulation of Bcl-2 and inactivation of Bax. Biochim Biophys Acta. 1823:2201–2209. 2012. View Article : Google Scholar : PubMed/NCBI
17	Derjuga A, Richard C, Crosato M, Wright PS, Chalifour L, Valdez J, Barraso A, Crissman HA, Nishioka W, Bradbury EM, et al: Expression of p21Waf1/Cip1 and cyclin D1 is increased in butyrate-resistant HeLa cells. J Biol Chem. 276:37815–37820. 2001.PubMed/NCBI
18	Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y and Sarkar FH: Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer. 119:2071–2077. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ley R, Balmanno K, Hadfield K, Weston C and Cook SJ: Activation of the ERK1/2 signaling pathway promotes phosphor-ylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem. 278:18811–18816. 2003. View Article : Google Scholar : PubMed/NCBI
20	Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G and Auberger P: Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 22:6785–6793. 2003. View Article : Google Scholar : PubMed/NCBI
21	Serpa J, Caiado F, Carvalho T, Torre C, Gonçalves LG, Casalou C, Lamosa P, Rodrigues M, Zhu Z, Lam EWF, et al: Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. J Biol Chem. 285:39211–39223. 2010. View Article : Google Scholar : PubMed/NCBI